Literature DB >> 11187891

Expression and activity of caspases 1 and 3 in myelodysplastic syndromes.

D Boudard1, O Sordet, C Vasselon, V Revol, M F Berthéas, D Freyssenet, A Viallet, S Piselli, D Guyotat, L Campos.   

Abstract

Myelodysplastic syndromes (MDS) are characterized by abnormal growth of committed progenitors in clonogenic assay, with reduced number of colonies and decreased colony/cluster ratio. It has been suggested that excessive apoptosis is the cause of marrow failure in MDS. We studied the expression of caspase-1 (interleukin-1beta-converting enzyme, ICE) and caspase-3 (CPP32/apopain) in marrow mononuclear cells, and the growth pattern of committed progenitors in a series of 83 MDS cases. The percentage of apoptotic cells as detected by TUNEL technique, and the percentage of caspase-3-positive cells were significantly higher in refractory anemia (RA) and RA with ringed sideroblasts (RAS) than in chronic myelomonocytic leukemia (CMML), refractory anemia with excess of blasts (RAEB) and RAEB in transformation (RAEB-T). Spontaneous growth of CFU-GM was associated with a higher percentage of blasts, and with a lower expression of caspase-3 and caspase-1. The yield of CFU-E, BFU-E, and CFU-GM (in the presence of growth factors) was decreased by comparison to normal marrow, but large individual differences were observed in all cytological categories. Inhibition of caspase-1 and caspase-3 activities by specific inhibitors resulted in a significant increase of the production of all types of colonies (up to 50-fold of control). In the presence of caspase-3 inhibitor, the number of BFU-E and CFU-E was in the range of normal values in most cases of RA and RAS. In addition, caspase-1 and -3 protease activities were detectable by fluorogenic assay in all cases studied. Western blot analysis confirmed the expression of caspase-3, including the cleaved (activated)-p17 form in most cases of RA/RAS analyzed. It is concluded that caspase-3 is implicated in the increased apoptosis observed in MDS and that inhibition of its activity can restore at least partially the growth of committed progenitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11187891     DOI: 10.1038/sj.leu.2401959

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  The role of apoptosis in the pathogenesis of the myelodysplastic syndromes.

Authors:  Jane E Parker; Ghulam J Mufti
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

Review 3.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Authors:  Daniella B Kerbauy; H Joachim Deeg
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

4.  Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.

Authors:  Saskia Mc Langemeijer; Niccolo Mariani; Ruth Knops; Christian Gilissen; Rob Woestenenk; Theo de Witte; Gerwin Huls; Bert A van der Reijden; Joop H Jansen
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

Review 5.  Inflammasome Activation in Myeloid Malignancies-Friend or Foe?

Authors:  Nicola Andina; Nicolas Bonadies; Ramanjaneyulu Allam
Journal:  Front Cell Dev Biol       Date:  2022-01-27

6.  Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.

Authors:  Sara Galimberti; Francesca Guerrini; Flavia Salvi; Iacopo Petrini; Daniela Gioia; Emanuela Messa; Giuseppe A Palumbo; Daniela Cilloni; Mario Petrini; Alessandro Levis
Journal:  J Hematol Oncol       Date:  2012-09-10       Impact factor: 17.388

7.  Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase.

Authors:  Pascale Flandrin-Gresta; Françoise Solly; Carmen Mariana Aanei; Jérôme Cornillon; Emmanuelle Tavernier; Nathalie Nadal; Franck Morteux; Denis Guyotat; Eric Wattel; Lydia Campos
Journal:  Oncotarget       Date:  2012-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.